Want to see HK:1672 full AI Analyst Report?
1672 Stock Chart & Stats
HK$8.94
-HK$0.23(-2.51%)
At close: 4:00 PM EDT
HK$8.94
-HK$0.23(-2.51%)
Day’s Range― - ―
52-Week RangeHK$7.95 - HK$19.86
Previous CloseN/A
Volume1.64M
Average Volume (3M)8.30M
Market Cap
HK$11.73B
Enterprise ValueHK$9.00K
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$5.16M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 31, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,057,769,000
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.97
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.19Price Target Upside36.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt-to-equity materially reduces near-term solvency risk and preserves financing optionality. For a cash-burning biotech, low leverage lowers bankruptcy risk and gives management more time to advance assets or secure partnering/funding without immediate debt pressures.
Commercialization And Diversified Revenue ModelHaving commercial product sales plus licensing and service revenue provides multiple monetization paths. Commercial infrastructure to sell prescription medicines and potential milestone/royalty streams supports sustained cash flow upside if pipeline or partnered assets progress.
In-house R&D And Focused Therapeutic AreasA built R&D engine and collaborations in enduring therapeutic areas (antiviral, metabolic) sustain long-term value creation potential. Pipeline focus and development capabilities increase chances of future monetizable assets or partnerships that can reverse revenue weakness.
Bears Say
Severe Revenue CollapseA multi-year, large drop in revenues indicates loss of core sales or product disruptions that are unlikely to self-correct quickly. Structural revenue weakness undermines ability to cover fixed costs, support R&D, and sustain commercial operations without new product or partner-driven income.
Persistent And Accelerating Cash BurnOperating cash outflows have more than doubled versus 2023 and remain deeply negative, creating ongoing funding needs. This persistent burn raises financing risk, increases probability of dilution or asset sales, and constrains long-term strategic flexibility absent durable revenue recovery.
Negative Profitability And Equity ErosionNegative gross profit means costs exceed revenue at the unit level, signaling profound pricing or cost-structure issues. Sustained operating and net losses have driven negative ROE and declining equity, raising the risk that continued losses will erode shareholder value or force dilutive financing.
Ascletis Pharma, Inc. News
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$7.95 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$11.73B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Aug 31, 2026 which is in 20 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.326 earnings per share for the quarter, the consensus estimate of -HK$0.326 by HK$0.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,057,769,000 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.326 in its last earnings report, expectations of -HK$0.326. Following the earnings report the stock price went down -1.129%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascletis Pharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$12.19 (36.35% Upside)
HK$12.19 (36.35% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
612.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.80%
Trailing 12-Months
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma, Inc. (1672) is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of therapies, with a primary focus on antiviral and other disease areas. The company develops and markets prescription medicines and related products, and operates through a combination of in-house capabilities and external collaborations to advance drug candidates from clinical development to commercialization.
1672 Stock 12 Month Forecast
Average Price Target
HK$12.19
▲(36.35% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―